- Report
- February 2026
- 180 Pages
Global
From €4356EUR$4,850USD£3,721GBP
- Report
- January 2026
- 199 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2026
- 282 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- August 2025
- 186 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- May 2024
- 131 Pages
Global
From €2694EUR$2,999USD£2,301GBP
€3592EUR$3,999USD£3,068GBP
- Report
- July 2021
- 50 Pages
China
From €2335EUR$2,600USD£1,995GBP
- Report
- October 2024
- 101 Pages
Global
From €3500EUR$4,174USD£3,094GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,174USD£3,094GBP
- Report
- August 2026
- 50 Pages
Global
From €2380EUR$2,650USD£2,033GBP
- Report
- March 2025
- 109 Pages
China
From €1617EUR$1,800USD£1,381GBP
- Report
- March 2025
- 215 Pages
China
From €3593EUR$4,000USD£3,069GBP

Nifedipine is a calcium channel blocker used to treat high blood pressure and angina. It is a commonly prescribed cardiovascular drug, and is available in both immediate-release and extended-release formulations. Nifedipine is also used to treat preterm labor, Raynaud's phenomenon, and hypertrophic cardiomyopathy. It is generally well-tolerated, but can cause side effects such as headache, dizziness, and swelling.
Nifedipine is available in both generic and brand-name formulations. Brand-name formulations include Procardia, Adalat, and Nifediac. Generic formulations are available from a variety of manufacturers.
In the Nifedipine market, some of the major players include Pfizer, Bayer, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more